Supp_Figure_1a.tif (203.6 kB)

Supp_Figure_1a: Economic burden in treated Japanese patients with relapsed/refractory large B-cell lymphoma.tif

figure

posted on 2021-08-20, 12:32 authored by Saaya Tsutsué, Shinichi Makita, Jingbo Yi, Bruce Crawford

Supplemental Figure 1a - Patient attrition for 2L and 3L r/r DLBCL patients - Main analysis cohort

Funding

Celgene KK

Brystol Myers Squibb Company

History

Usage metrics

Read the peer-reviewed publication

Economic burden in treated Japanese patients with relapsed/refractory large B-cell lymphoma

Future Oncology

Categories

Cancer therapy (excl. chemotherapy and radiation therapy)

Keywords

relapse refractory Diffuse Large B-cell Lymphoma Salvage Chemotherapy retrospective database study cost COVID-19 Japanese Cancer Therapy (excl. Chemotherapy and Radiation Therapy)

Licence

CC BY-NC-ND 4.0

Exports